JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB210189

PE Anti-PD-L1 antibody [10F.9G2]

Be the first to review this product! Submit a review

|

(2 Publications)

Rat Monoclonal PD-L1 antibody - conjugated to PE. Suitable for Flow Cyt and reacts with Mouse samples. Cited in 2 publications. Immunogen corresponding to Synthetic Nucleic Acid within Mouse Cd274.

View Alternative Names

CD274, B7h1, Pdcd1l1, Pdcd1lg1, Pdl1, Cd274, Programmed cell death 1 ligand 1, PD-L1, PDCD1 ligand 1, Programmed death ligand 1, B7 homolog 1, B7-H1

1 Images
Flow Cytometry - PE Anti-PD-L1 antibody [10F.9G2] (AB210189)
  • Flow Cyt

Supplier Data

Flow Cytometry - PE Anti-PD-L1 antibody [10F.9G2] (AB210189)

Flow cytometric analysis of mouse C57BI/6 splenocytes labeling PD-L1 with 0.25 μg ab210189 (solid line) or 0.25 μg PE rat IgG2b isotype control (dashed line).

Key facts

Host species

Rat

Clonality

Monoclonal

Clone number

10F.9G2

Isotype

IgG2b

Light chain type

kappa

Conjugation

PE

Excitation/Emission

Ex: 480;565nm, Em: 578nm

Carrier free

No

Reacts with

Mouse

Applications

Flow Cyt

applications

Immunogen

CHO-mPD-L1 transfectants. Database link Q9EP73

style
left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "FlowCyt" : {"fullname" : "Flow Cytometry", "shortname":"Flow Cyt"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Mouse": { "FlowCyt-species-checked": "testedAndGuaranteed", "FlowCyt-species-dilution-info": "", "FlowCyt-species-notes": "<p>Use 0.25 μg.</p>" } } }
style
left-column
style
left-column

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Purification notes
ab210189 was purified from tissue culture supernatant via affinity chromatography. The purified antibody was conjugated under optimal conditions, with unreacted dye removed from the preparation.
Storage buffer
pH: 7.2 Preservative: 0.09% Sodium azide Constituents: 0.87% Sodium chloride, 0.12% Sodium dihydrogen phosphate, 0.1% Gelatin
Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
+4°C
Storage information
Store in the dark
style
left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

PD-L1 also known as Programmed Death-Ligand 1 or CD274 is a protein involved in immune modulation. Mechanically PD-L1 interacts with its receptors particularly PD-1 to regulate cellular immune responses. This transmembrane protein has a calculated molecular weight of approximately 33 kDa. PD-L1 is expressed on various cell types including tumor cells and immune cells such as dendritic cells macrophages and B cells. Its expression is often upregulated in response to inflammatory cytokines.
Biological function summary

PD-L1 plays a central role in immune evasion mechanisms utilized by tumors. It is not part of a larger protein complex but directly interacts with PD-1 and CD80. When PD-L1 binds to PD-1 it sends inhibitory signals leading to decreased T cell activation and proliferation allowing cancer cells to avoid immune destruction. PD-L1 expression provides a mechanism for tumors to suppress immune surveillance facilitating tumor progression.

Pathways

PD-L1 is integral to the immune checkpoint pathway which is an important regulator of immune response. The interaction between PD-L1 and PD-1 provides a mechanism for immune tolerance which is part of the broader adaptive immune system pathway. PD-L1 is related to other immune checkpoint proteins such as CTLA-4 in its function to limit autoreactivity and promote immune homeostasis.

PD-L1 is most associated with cancer particularly in tumors such as melanoma and non-small cell lung cancer. PD-L1 expression on tumor cells often correlates with poor prognosis. PD-L1 directly interacts with PD-1 in these cancers a target for immunotherapies such as checkpoint inhibitors which aim to block this interaction and restore immune activity against tumors. PD-L1 involvement extends to autoimmune disorders where altered expression can impact tolerance and lead to immune-related tissue damage.
style
left-column
style
left-column

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:
style
left-column

Target data

Plays a critical role in induction and maintenance of immune tolerance to self (PubMed : 11238124). As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response (PubMed : 11238124). Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (PubMed : 11015443, PubMed : 12719480).. The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival (PubMed : 12218188, PubMed : 27281199). The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function (PubMed : 12218188). The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy (PubMed : 12218188).
See full target information Cd274
style
left-column

Publications (2)

Recent publications for all applications. Explore the full list and refine your search

Nature communications 9:4777 PubMed30429468

2018

MR imaging tracking of inflammation-activatable engineered neutrophils for targeted therapy of surgically treated glioma.

Applications

Unspecified application

Species

Unspecified reactive species

Meiying Wu,Haixian Zhang,Changjun Tie,Chunhong Yan,Zhiting Deng,Qian Wan,Xin Liu,Fei Yan,Hairong Zheng

Microcirculation (New York, N.Y. : 1994) 9:133-45 PubMed11932780

2002

Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells.

Applications

Unspecified application

Species

Unspecified reactive species

Michael J Eppihimer,Jason Gunn,Gordon J Freeman,Edward A Greenfield,Tetyana Chernova,Jamie Erickson,John P Leonard
View all publications
style
left-column
style
left-column
style
right-column

Alternative Products

Primary Antibodies

AB209960

Alexa Fluor® 647 Anti-PD-L1 antibody [28-8] - Extracellular domain

RabMAb|Recombinant

Immunocytochemistry/ Immunofluorescence - Alexa Fluor® 647 Anti-PD-L1 antibody [28-8] - Extracellular domain (AB209960)

  • 0
  • 0
Primary Antibodies

AB213480

Anti-PD-L1 antibody [EPR20529]

RabMAb|Recombinant|KO Validated|20ul selling size

Immunocytochemistry/ Immunofluorescence - Anti-PD-L1 antibody [EPR20529] (AB213480)

  • 5
  • 5
Primary Antibodies

AB213524

Anti-PD-L1 antibody [EPR19759]

BOND RX™ Validated|RabMAb|Recombinant|KO Validated|20ul selling size

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD-L1 antibody [EPR19759] (AB213524)

  • 5
  • 1
Primary Antibodies

AB205921

Anti-PD-L1 antibody [28-8]

BOND RX™ Validated|20ul selling size|Recombinant|KO Validated|Advanced Validation|RabMAb

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD-L1 antibody [28-8] (AB205921)

  • 4
  • 15
Primary Antibodies

AB228415

Anti-PD-L1 antibody [73-10]

BOND RX™ Validated|KO Validated|RabMAb|Recombinant

Immunohistochemistry (Frozen sections) - Anti-PD-L1 antibody [73-10] (AB228415)

  • 5
  • 1
Primary Antibodies

AB274896

Alexa Fluor® 555 Anti-PD-L1 antibody [73-10]

BOND RX™ Validated|RabMAb|Recombinant|Trial Size

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Alexa Fluor® 555 Anti-PD-L1 antibody [73-10] (AB274896)

  • 4
  • 1
Primary Antibodies

AB228462

Anti-PD-L1 antibody [SP142] - C-terminal

BOND RX™ Validated|20ul selling size|RabMAb|Advanced Validation|Recombinant

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD-L1 antibody [SP142] - C-terminal (AB228462)

  • 5
  • 2

Complementary Products

Assay Kits

AB277712

Human PD-L1 ELISA Kit [28-8]

Recombinant|SimpleStep

ELISA - Human PD-L1 ELISA Kit [28-8] (AB277712)

  • 0
  • 0
Primary Antibodies

AB201825

Alexa Fluor® 647 Anti-PD1 antibody [EPR4877(2)]

RabMAb|Recombinant

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Alexa Fluor® 647 Anti-PD1 antibody [EPR4877(2)] (AB201825)

  • 5
  • 1
Secondary Antibodies

AB150077

Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488)

Immunocytochemistry/ Immunofluorescence - Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (AB150077)

  • 5
  • 20
Primary Antibodies

AB277275

Alexa Fluor® 488 Anti-CD4 antibody [EPR19514]

BOND RX™ Validated|RabMAb|Recombinant

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Alexa Fluor® 488 Anti-CD4 antibody [EPR19514] (AB277275)

  • 1
  • 1
Primary Antibodies

AB210232

PE/Cy7® Anti-FOXP3 antibody [3G3]

Flow Cytometry (Intracellular) - PE/Cy7® Anti-FOXP3 antibody [3G3] (AB210232)

  • 0
  • 0

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com